News for Silence Therapeutics plc (SLN)

Silence Therapeutics plc (NASDAQ:SLN) Q4 2024 Earnings Call February 27, 2025 8:00 AM ETCompany ParticipantsGem Hopkins - Vice President, Investor Relations...

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) made a notable acquisition by purchasing 7,197,951 shares of Silence Therapeutics PLC. This transac

Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding challenges for the company. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock update.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

We recently compiled a list of the 10 Oversold Global Stocks To Buy Right Now. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against the other oversold...

Silence Therapeutics plc (”œSilence” or the ”œCompany”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) the

Silence Therapeutics plc, Nasdaq: SLN (”œSilence” or the ”œCompany”), a global clinical stage biotechnology company committed to transforming people's li

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28%

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Silence Therapeutics plc, Nasdaq: SLN (”œSilence” or the ”œCompany”), a global clinical stage biotechnology company committed to transforming people's li

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds.

Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data

Silence Therapeutics receives $2 million from Hansoh Pharma

/PRNewswire/ -- DelveInsight's Atherosclerotic Cardiovascular Disease Market Insights report includes a comprehensive understanding of current treatment...

/PRNewswire/ -- The RNAi drug delivery market is expected to grow by USD 109.73 billion from 2022 to 2027, progressing at a CAGR of 20.83% as per the latest...

/PRNewswire/ -- The